Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24731330 | 0.78 | AR (0.64) | ARPOLBMAPTKMT2A | |
| SCHEMBL24731327 | 0.78 | AR (0.64) | ARPOLBMAPTKMT2A | |
| SCHEMBL2328624 | 0.78 | ADRB2 (0.42) | AR | |
| SCHEMBL13979980 | 0.78 | ITGB3 (0.53) | ITGB3ITGA2BS1PR1S1PR4S1PR5 | |
| SCHEMBL6360882 | 0.77 | AR (0.61) | ARPOLBMAPTKMT2A | |
| SCHEMBL13675777 | 0.75 | S1PR1 (0.51) | S1PR1S1PR4S1PR5S1PR2S1PR3 | |
| SCHEMBL12251782 | 0.74 | ITGB3 (0.48) | ITGB3ITGA2BFFAR1 | |
| SCHEMBL2328749 | 0.74 | LMNA (0.51) | S1PR1S1PR4S1PR5S1PR2S1PR3 | |
| SCHEMBL11666008 | 0.73 | AR (0.57) | ARPOLBMAPTKMT2A | |
| SCHEMBL27635306 | 0.73 | AR (0.57) | ARPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241528-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-10167266-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-8846688-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8227474-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8198286-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1485360-B1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-1485360-A4 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060142306-A1 | Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents | CYFI, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-6858615-B2 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; 2,6-diaminopyrazine derivatives | PARION SCIENCES, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1485360-A2 | SODIUM CHANNEL BLOCKERS | Johnson, Michael R. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040229884-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; long half-life on mucosal surfaces; pyrazinoylguanidine derivatives | PARION SCIENCES, INC. | 2004-11-18 | — | — | US | disclosed |
| US-20040204425-A1 | Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders | PARION SCIENCES, INC. (US) | 2004-10-14 | — | — | US | disclosed |
| US-20040198749-A1 | Broncholdilator agents; hydration of mucous membranes; respiratory system disorders | PARION SCIENCES, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20040198748-A1 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | PARION SCIENCES, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20030199456-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; 2,6-diaminopyrazine derivatives | CYFI, INC. (US) | 2003-10-23 | — | — | US | disclosed |
| WO-2003070182-A2 | SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | AR 3361/4885ITGB3 1552/4885ITGA2B 831/4885 |
| US-10167266-B2 | Sodium channel blockers | SCNN1B, SCNN1A, SCNN1G | AR 2915/4885ITGB3 1092/4885ITGA2B 1003/4885 |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | AR 3361/4885ITGB3 1552/4885ITGA2B 831/4885 |
| US-20040229884-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; long half-life on mucosal surfaces; pyrazinoylguanidine derivatives | SCNN1B, KCNN2, SCNN1G | AR 3063/4885ITGB3 2417/4885ITGA2B 1650/4885 |
| US-20060142306-A1 | Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents | ADRB2, ADRB3, ADRA1D | AR 1164/4885ITGB3 3746/4885ITGA2B 4134/4885 |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | AR 3361/4885ITGB3 1552/4885ITGA2B 831/4885 |
| US-20040204425-A1 | Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders | CFTR, TRPC4, TRPC5 | AR 4089/4885ITGB3 3624/4885ITGA2B 4532/4885 |
| US-20040198749-A1 | Broncholdilator agents; hydration of mucous membranes; respiratory system disorders | AQP1, TRPV1, AQP3 | AR 3951/4885ITGB3 3522/4885ITGA2B 4218/4885 |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | AR 3361/4885ITGB3 1552/4885ITGA2B 831/4885 |
| US-20030199456-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; 2,6-diaminopyrazine derivatives | SCNN1B, KCNN2, KCNN1 | AR 3901/4885ITGB3 2537/4885ITGA2B 1749/4885 |
| US-20040198748-A1 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | HRH4, HRH2, HRH1 | AR 2571/4885ITGB3 1035/4885ITGA2B 2018/4885 |
| US-20190241528-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | AR 3361/4885ITGB3 1552/4885ITGA2B 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.